These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3955402)

  • 21. [Mexiletine, an anti-arrhythmia agent for acute stage of myocardial infarction].
    Hayakawa H; Ino T
    Nihon Rinsho; 1983 Dec; 41(12):2748-55. PubMed ID: 6674559
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of rifampicin treatment on the kinetics of mexiletine.
    Pentikäinen PJ; Koivula IH; Hiltunen HA
    Eur J Clin Pharmacol; 1982; 23(3):261-6. PubMed ID: 6129140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetic studies with mexiletine in patients with renal insufficiency].
    Herbinger W; Kramar R; Fridrik M; Häselbarth V; Pollmann WP
    Adv Clin Pharmacol; 1978; 16():17-27. PubMed ID: 685748
    [No Abstract]   [Full Text] [Related]  

  • 24. Mexiletine in human blood and breast milk.
    Lewis AM; Patel L; Johnston A; Turner P
    Postgrad Med J; 1981 Sep; 57(671):546-7. PubMed ID: 7329891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mexiletine clearance during peritoneal dialysis.
    Guay DR; Meatherall RC; Ferguson I; Smith H; Light B
    Br J Clin Pharmacol; 1985 Jun; 19(6):857-8. PubMed ID: 4027132
    [No Abstract]   [Full Text] [Related]  

  • 26. Mexiletine removal by peritoneal dialysis.
    Jones TE; Reece PA; Fisher GC
    Eur J Clin Pharmacol; 1983; 25(6):839-40. PubMed ID: 6662185
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    Eur J Clin Pharmacol; 1983; 25(6):773-7. PubMed ID: 6662176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease.
    Nitsch J; Steinbeck G; Lüderitz B
    Eur Heart J; 1983 Nov; 4(11):810-4. PubMed ID: 6653593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dissolution and oral bioavailability of mexiletine capsules modified for clinical trial. A preliminary report.
    Chan K; Tse J; Deeks PA; Pilling M
    Methods Find Exp Clin Pharmacol; 1983 Sep; 5(7):471-8. PubMed ID: 6668966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic parameters in patients treated with oral mexiletine.
    Vozeh S; Katz G; Steiner V; Follath F
    Eur J Clin Pharmacol; 1982; 23(5):445-51. PubMed ID: 7151850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    J Cardiovasc Pharmacol; 1984; 6(1):1-6. PubMed ID: 6199590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers.
    Johnston A; Burgess CD; Warrington SJ; Wadsworth J; Hamer NA
    Br J Clin Pharmacol; 1979 Oct; 8(4):349-52. PubMed ID: 41549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mexitil (Mexiletine). A new antiarrhythmic agent].
    Bjerregaard P
    Ugeskr Laeger; 1980 Oct; 142(43):2855-6. PubMed ID: 7445202
    [No Abstract]   [Full Text] [Related]  

  • 34. A comparison of mexiletine and a slow release formulation of mexiletine in patients admitted to a coronary care unit [proceedings].
    Boyle DM; Chapman C; Kinney C; McIlmoyle EL; Salathia K; Shanks RG
    Br J Clin Pharmacol; 1980 Mar; 9(3):293P. PubMed ID: 7362748
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of ventricular arrhythmias with mexiletine].
    Trenckmann H; Neugebauer A; Krosse B
    Z Gesamte Inn Med; 1982 May; 37(9):259-62. PubMed ID: 7048773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.
    Mitchell BG; Clements JA; Pottage A; Prescott LF
    Br J Clin Pharmacol; 1983 Sep; 16(3):281-4. PubMed ID: 6626420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between plasma levels, salivary concentrations and urinary excretion rates of mexiletene [proceedings].
    Beckett AH; Chidomere EC
    J Pharm Pharmacol; 1976 Dec; 28 Suppl():58P. PubMed ID: 12335
    [No Abstract]   [Full Text] [Related]  

  • 38. Hemodynamic, electrocardiographic and toxic effects of the intravenous administration of increasing doses of mexiletine in the dog. Comparison with similar effects produced by other antiarrhythmics.
    Carlier J
    Acta Cardiol Suppl; 1980; (25):81-100. PubMed ID: 6966456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of age on the pharmacokinetics of mexiletine.
    el Allaf D; Carlier J; Dressé A
    Int J Clin Pharmacol Res; 1986; 6(4):303-7. PubMed ID: 3759283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption and antiarrhythmic efficacy of sustained-release mexiletine.
    Holt DW; Chadwick DE; Campbell RW
    Clin Ther; 1983; 5(3):268-78. PubMed ID: 6850720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.